Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 1/20 | 0.43 |
| ▸ | BCHE | P06276 | 2/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.41 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.41 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.41 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.41 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.41 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | CTSV | O60911 | 1/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19333652 | 1.00 | TACR1 (0.43) | TACR1BCHEACHEPSEN1PSEN2 | |
| SCHEMBL6280088 | 0.88 | CHRNB4 (0.41) | TACR1 | |
| SCHEMBL6280080 | 0.88 | CHRNB4 (0.41) | TACR1 | |
| SCHEMBL6280084 | 0.88 | CHRNB4 (0.41) | TACR1 | |
| SCHEMBL3961461 | 0.86 | KCNA5 (0.42) | TACR1BCHEACHEPSEN1PSEN2 | |
| SCHEMBL3961467 | 0.86 | KCNA5 (0.42) | TACR1BCHEACHEPSEN1PSEN2 | |
| SCHEMBL19333763 | 0.86 | KCNA5 (0.42) | TACR1BCHEACHEPSEN1PSEN2 | |
| SCHEMBL3961462 | 0.86 | KCNA5 (0.42) | TACR1BCHEACHEPSEN1PSEN2 | |
| SCHEMBL3961464 | 0.86 | KCNA5 (0.42) | TACR1BCHEACHEPSEN1PSEN2 | |
| Hydrochloric Acid SCHEMBL6234960 | 0.85 | TSHR (0.41) | TACR1BCHEACHEPSEN1PSEN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 187 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019011879-A1 | THERAPEUTIC FOR TREATING CAPILLARY LEAK SYNDROME | HENNING RAINER (CH) | 2019-01-17 | — | — | WO | claimed |
| US-8486370-B2 | Heterocyclic ligands for integrin imaging and therapy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-07-16 | — | — | US | claimed |
| US-8088890-B2 | Peptides and peptidomimetic compounds, the manufacturing thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition | FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH (AT) | 2012-01-03 | — | — | US | claimed |
| EP-2334324-A2 | BBETA (15-42) AND ITS ANALOGUES COMBINED WITH CYCLOSPORINE FOR TREATMENT OF REPERFUSION INJURY | Fibrex Medical Research & Development GmbH (AT) | 2011-06-22 | — | — | EP | claimed |
| EP-2328925-A1 | PEPTIDES AND PEPTIDOMIMETIC COMPOUNDS, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION | Fibrex Medical Research & Development GmbH (AT) | 2011-06-08 | — | — | EP | claimed |
| US-7884074-B2 | Compounds and methods for prevention and/or treatment of inflammation using the same | Ikaria Development Subsidiary Two, LLC (US) | 2011-02-08 | — | — | US | claimed |
| EP-2274328-A1 | PEPTIDES, PEPTIDOMIMETICS AND DERIVATIVES THEREOF, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION | Fibrex Medical Research & Development GmbH (AT) | 2011-01-19 | — | — | EP | claimed |
| US-20100310455-A1 | Heterocyclic Ligands for Integrin Imaging and Therapy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-12-09 | — | — | US | claimed |
| US-20100099602-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE FOR THE PREVENTION AND TREATMENT OF HYPOXIC INJURY | FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH (AT) | 2010-04-22 | — | — | US | claimed |
| WO-2010043972-A2 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE FOR THE PREVENTION AND TREATMENT OF HYPOXIC INJURY | FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH (AT) | 2010-04-22 | — | — | WO | claimed |
| WO-2010034041-A1 | PEPTIDES AND PEPTIDOMIMETIC COMPOUNDS, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION | FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH (AT) | 2010-04-01 | — | — | WO | claimed |
| US-20100081787-A1 | PEPTIDES AND PEPTIDOMIMETIC COMPOUNDS, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION | FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH (AT) | 2010-04-01 | — | — | US | claimed |
| US-20090286739-A1 | PEPTIDES, PEPTIDOMIMETICS AND DERIVATIVES THEREOF, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION | FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH (AT) | 2009-11-19 | — | — | US | claimed |
| WO-2009137850-A1 | PEPTIDES, PEPTIDOMIMETICS AND DERIVATIVES THEREOF, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION | FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH (AT) | 2009-11-19 | — | — | WO | claimed |
| US-7576175-B2 | Amino acid terminated diphenylurea derivatives; display high binding affinity, specificity, and stability; use in treating cancer, inflammatory diseases, and autoimmune diseases | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-08-18 | — | — | US | claimed |
| WO-2008031016-A2 | HETEROCYCLIC LIGANDS FOR INTEGRIN IMAGING AND THERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-03-13 | — | — | WO | claimed |
| WO-2005122379-A9 | ALPHA-4 BETA-1 INTEGRIN LIGANDS FOR IMAGING AND THERAPY | UNIV CALIFORNIA (US) | 2006-03-09 | — | — | WO | claimed |
| US-20060019900-A1 | Alpha-4 beta-1 integrin ligands for imaging and therapy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-01-26 | — | — | US | claimed |
| WO-2005122379-A2 | ALPHA-4 BETA-1 INTEGRIN LIGANDS FOR IMAGING AND THERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-12-22 | — | — | WO | claimed |
| WO-2026105061-A1 | ANTIBODY-DRUG CONJUGATES THAT BIND CDCP1 AND USES THEREOF | PHEON THERAPEUTICS LTD (GB) | 2026-05-21 | — | — | WO | disclosed |
| WO-2026090584-A2 | METHODS OF TREATING PERIPHERAL NERVOUS SYSTEM MYELINATION CONDITIONS | Artery Therapeutics, Inc. (US) | 2026-04-30 | — | — | WO | disclosed |
| EP-4731270-A1 | COMBINATION THERAPY WITH PEPTIDE RECEPTOR RADIONUCLIDE AND DNA REPAIR INHIBITOR | The Regents of The University of California (US) | 2026-04-29 | — | — | EP | disclosed |
| US-20260083852-A1 | PROTEOGLYCAN MIMETICS FOR ENHANCED WOUND HEALING, ANGIOGENESIS, AND VASCULAR REPAIR | UNIV CALIFORNIA (US) | 2026-03-26 | — | — | US | disclosed |
| US-12485182-B2 | Proteoglycan mimetics for enhanced wound healing, angiogenesis, and vascular repair | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-12-02 | — | — | US | disclosed |
| EP-4633738-A1 | CYTOTOXIC COMPOUNDS | Pheon Therapeutics Ltd (GB) | 2025-10-22 | — | — | EP | disclosed |
| CN-112672747-B | Peptides for activating cell signaling in osteoprogenitor cells | 加利福尼亚大学董事会 | 2025-02-18 | — | — | CN | disclosed |
| WO-2024263637-A1 | COMBINATION THERAPY WITH PEPTIDE RECEPTOR RADIONUCLIDE AND DNA REPAIR INHIBITOR | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-12-26 | — | — | WO | disclosed |
| US-12157778-B2 | Peptides for activation of cell signaling in osteoprogenitor cells | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-12-03 | — | — | US | disclosed |
| US-12023391-B2 | Alpha(v)beta(6) integrin-binding peptides and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-07-02 | — | — | US | disclosed |
| WO-2024127333-A1 | CYTOTOXIC COMPOUNDS | PHEON THERAPEUTICS LTD (GB) | 2024-06-20 | — | — | WO | disclosed |
| WO-2024127332-A1 | CYTOTOXIC COMPOUNDS | PHEON THERAPEUTICS LTD (GB) | 2024-06-20 | — | — | WO | disclosed |
| US-20240101601-A1 | BI-TERMINAL PEGYLATED INTEGRIN-BINDING PEPTIDES AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-03-28 | — | — | US | disclosed |
| CN-109563135-B | Alpha (V) beta (6) integrin binding peptides and methods of use thereof | 加利福尼亚大学董事会 | 2024-01-23 | — | — | CN | disclosed |
| US-20230346960-A1 | PROTEOGLYCAN MIMETICS FOR ENHANCED WOUND HEALING, ANGIOGENESIS, AND VASCULAR REPAIR | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-11-02 | — | — | US | disclosed |
| CN-116348128-A | Bβ15-42 for treating viral endopdermatitis | F4医药有限责任公司 | 2023-06-27 | — | — | CN | disclosed |
| US-20230183317-A1 | METHODS OF DETECTING AND TREATING LUNG DAMAGE IN RESPIRATORY-RELATED VIRAL INFECTIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-06-15 | — | — | US | disclosed |
| EP-4153310-A1 | BBETA-15-42 FOR THE TREATMENT OF VIRAL ENDOTHELITIS | F4 Pharma GmbH (AT) | 2023-03-29 | — | — | EP | disclosed |
| US-11612663-B2 | Proteoglycan mimetics for enhanced wound healing, angiogenesis, and vascular repair | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-03-28 | — | — | US | disclosed |
| EP-4146268-A2 | METHODS OF DETECTING AND TREATING LUNG DAMAGE IN RESPIRATORY-RELATED VIRAL INFECTIONS | The Regents of the University of California (US) | 2023-03-15 | — | — | EP | disclosed |
| US-11591369-B2 | Alpha(v)beta(6) integrin-binding peptides and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-02-28 | — | — | US | disclosed |
| US-20230040236-A1 | Diamine-Linked Melanocortin Receptor-Specific Cyclic Peptides for Ocular Indications | PALATIN TECHNOLOGIES, INC. (US) | 2023-02-09 | — | — | US | disclosed |
| EP-4100040-A1 | DIAMINE-LINKED RECEPTOR-SPECIFIC CYCLIC PEPTIDES | Palatin Technologies, Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| US-20220363719-A1 | Reverse Amide-Linked Melanocortin Receptor-Specific Cyclic Peptides | PALATIN TECHNOLOGIES, INC. (US) | 2022-11-17 | — | — | US | disclosed |
| US-11485758-B2 | Bi-terminal pegylated integrin-binding peptides and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-11-01 | — | — | US | disclosed |
| US-20220313867-A1 | ENGINEERED SCAFFOLDS FOR VASCULARIZED TISSUE REPAIR | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-10-06 | — | — | US | disclosed |
| EP-3131566-B1 | BI-TERMINAL PEGYLATED INTEGRIN-BINDING PEPTIDES AND METHODS OF USE THEREOF | UNIV CALIFORNIA (US) | 2022-10-05 | — | — | EP | disclosed |
| US-11434267-B2 | Peptides having reduced toxicity that stimulate cholesterol efflux | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-09-06 | — | — | US | disclosed |
| US-11286280-B2 | Melanocortin-1 receptor-specific peptides for cytokine storm and inflammation therapy | PALATIN TECHNOLOGIES, INC. (US) | 2022-03-29 | — | — | US | disclosed |
| US-20220088146-A1 | Melanocortin Receptor-Specific Peptide Formulations and Methods for Gastrointestinal Tract-Specific Delivery | PALATIN TECHNOLOGIES INC (US) | 2022-03-24 | — | — | US | disclosed |
| CN-109196004-B | Engineered scaffold for vascularized tissue repair | 加利福尼亚大学董事会 | 2022-03-18 | — | — | CN | disclosed |
| US-20220047730-A1 | ALPHA(V)BETA(6) INTEGRIN-BINDING PEPTIDES AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-02-17 | — | — | US | disclosed |
| US-11246961-B2 | Engineered scaffolds for vascularized tissue repair | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-02-15 | — | — | US | disclosed |
| US-20210395302-A1 | PEPTIDES FOR ACTIVATION OF CELL SIGNALING IN OSTEOPROGENITOR CELLS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-12-23 | — | — | US | disclosed |
| EP-3426700-B1 | ENGINEERED SCAFFOLDS FOR VASCULARIZED TISSUE REPAIR | UNIV CALIFORNIA (US) | 2021-12-15 | — | — | EP | disclosed |
| US-11185601-B2 | Alpha(v)beta(6) integrin-binding peptides and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-11-30 | — | — | US | disclosed |
| WO-2021233971-A1 | BBETA-15-42 FOR THE TREATMENT OF VIRAL ENDOTHELITIS | Johann Wolfgang Goethe-Universität Frankfurt am Main (DE) | 2021-11-25 | — | — | WO | disclosed |
| EP-3912679-A1 | BBETA-15-42 FOR THE TREATMENT OF VIRAL ENDOTHELITIS | Johann Wolfgang Goethe-Universität Frankfurt am Main (DE) | 2021-11-24 | — | — | EP | disclosed |
| WO-2021226432-A2 | METHODS OF DETECTING AND TREATING LUNG DAMAGE IN RESPIRATORY-RELATED VIRAL INFECTIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-11-11 | — | — | WO | disclosed |
| US-20210340181-A1 | ALPHA(V)BETA(6) INTEGRIN-BINDING PEPTIDES AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-11-04 | — | — | US | disclosed |
| EP-3453711-B1 | LLP2A- BISPHOSPHONATE CONJUGATES FOR OSTEOPOROSIS TREATMENT | UNIV CALIFORNIA (US) | 2021-08-18 | — | — | EP | disclosed |
| US-11091529-B2 | Peptides having reduced toxicity that stimulate cholesterol efflux | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-08-17 | — | — | US | disclosed |
| WO-2021158463-A1 | DIAMINE-LINKED RECEPTOR-SPECIFIC CYCLIC PEPTIDES | PALATIN TECHNOLOGIES, INC. (US) | 2021-08-12 | — | — | WO | disclosed |
| EP-3846858-A1 | ALPHA(V)BETA(6) INTEGRIN-BINDING PEPTIDES AND METHODS OF USE THEREOF | The Regents of the University of California (US) | 2021-07-14 | — | — | EP | disclosed |
| US-20210206804-A1 | BI-TERMINAL PEGYLATED INTEGRIN-BINDING PEPTIDES AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-07-08 | — | — | US | disclosed |
| US-20210171586-A1 | PEPTIDES HAVING REDUCED TOXICITY THAT STIMULATE CHOLESTEROL EFFLUX | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-06-10 | — | — | US | disclosed |
| CN-106573031-B | Double-ended pegylated integrin-binding peptides and methods of use thereof | 加利福尼亚大学董事会 | 2021-05-28 | — | — | CN | disclosed |
| CN-112672747-A | Peptides for activating cell signalling in osteoprogenitor cells | 加利福尼亚大学董事会 | 2021-04-16 | — | — | CN | disclosed |
| US-20210093728-A1 | PROTEOGLYCAN MIMETICS FOR ENHANCED WOUND HEALING, ANGIOGENESIS, AND VASCULAR REPAIR | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-04-01 | — | — | US | disclosed |
| US-10919932-B2 | Bi-terminal pegylated integrin-binding peptides and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-02-16 | — | — | US | disclosed |
| EP-3768245-A1 | MELANOCORTIN RECEPTOR-SPECIFIC PEPTIDE FORMULATIONS AND METHODS FOR GASTROINTESTINAL TRACT-SPECIFIC DELIVERY | Palatin Technologies, Inc. (US) | 2021-01-27 | — | — | EP | disclosed |
| US-20200369723-A1 | LLP2A-BISPHOSPHONATE CONJUGATES FOR OSTEOPOROSIS TREATMENT | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-11-26 | — | — | US | disclosed |
| US-20200339631-A1 | Melanocortin-1 Receptor-Specific Peptides for Cytokine Storm and Inflammation Therapy | PALATIN TECHNOLOGIES INC (US) | 2020-10-29 | — | — | US | disclosed |
| US-10774118-B2 | Peptides having reduced toxicity that stimulate cholesterol efflux | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-09-15 | — | — | US | disclosed |
| US-10632171-B2 | Melanocortin receptor-specific peptides | PALATIN TECHNOLOGIES, INC. (US) | 2020-04-28 | — | — | US | disclosed |
| US-20190328910-A1 | ALPHA(V)BETA(6) INTEGRIN-BINDING PEPTIDES AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-10-31 | — | — | US | disclosed |
| WO-2019183472-A1 | MELANOCORTIN RECEPTOR-SPECIFIC PEPTIDE FORMULATIONS AND METHODS FOR GASTROINTESTINAL TRACT-SPECIFIC DELIVERY | PALATIN TECHNOLOGIES, INC. (US) | 2019-09-26 | — | — | WO | disclosed |
| EP-2983687-B1 | PEPTIDES HAVING REDUCED TOXICITY THAT STIMULATE CHOLESTEROL EFFLUX | UNIV CALIFORNIA (US) | 2019-09-04 | — | — | EP | disclosed |
| US-20190247539-A1 | ENGINEERED SCAFFOLDS FOR VASCULARIZED TISSUE REPAIR | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-08-15 | — | — | US | disclosed |
| US-20190216887-A1 | Melanocortin Receptor-Specific Peptides | PALATIN TECHNOLOGIES INC (US) | 2019-07-18 | — | — | US | disclosed |
| EP-3468984-A2 | ALPHA(V)BETA(6) INTEGRIN-BINDING PEPTIDES AND METHODS OF USE THEREOF | The Regents of the University of California (US) | 2019-04-17 | — | — | EP | disclosed |
| EP-3453711-A1 | LLP2A- BISPHOSPHONATE CONJUGATES FOR OSTEOPOROSIS TREATMENT | The Regents of the University of California (US) | 2019-03-13 | — | — | EP | disclosed |
| WO-2019011879-A1 | THERAPEUTIC FOR TREATING CAPILLARY LEAK SYNDROME | HENNING RAINER (CH) | 2019-01-17 | — | — | WO | disclosed |
| EP-3426700-A1 | ENGINEERED SCAFFOLDS FOR VASCULARIZED TISSUE REPAIR | The Regents of The University of California (US) | 2019-01-16 | — | — | EP | disclosed |
| EP-2504352-B1 | MELANOCORTIN-1 RECEPTOR-SPECIFIC CYCLIC PEPTIDES | PALATIN TECHNOLOGIES INC (US) | 2018-11-14 | — | — | EP | disclosed |
| US-10106578-B2 | Melanocortin-1 receptor-specific linear peptides | PALATIN TECHNOLOGIES, INC. (US) | 2018-10-23 | — | — | US | disclosed |
| US-20180298066-A1 | PEPTIDES HAVING REDUCED TOXICITY THAT STIMULATE CHOLESTEROL EFFLUX | UNITED STATES DEPARTMENT OF ENERGY | 2018-10-18 | — | — | US | disclosed |
| EP-3386484-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF THERAPEUTIC AGENTS | ModernaTX, Inc. (US) | 2018-10-17 | — | — | EP | disclosed |
| EP-2753626-B1 | LLP2A-BISPHOSPHONATE CONJUGATES FOR OSTEOPOROSIS TREATMENT | UNIV CALIFORNIA (US) | 2018-08-08 | — | — | EP | disclosed |
| US-10017551-B2 | Peptides having reduced toxicity that stimulate cholesterol efflux | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-07-10 | — | — | US | disclosed |
| WO-2017218569-A2 | ALPHA(V)BETA(6) INTEGRIN-BINDING PEPTIDES AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-12-21 | — | — | WO | disclosed |
| EP-2440227-B1 | MELANOCORTIN RECEPTOR-SPECIFIC PEPTIDES | PALATIN TECHNOLOGIES INC (US) | 2017-10-18 | — | — | EP | disclosed |
| US-20170283480-A1 | PEPTIDES HAVING REDUCED TOXICITY THAT STIMULATE CHOLESTEROL EFFLUX | UNITED STATES DEPARTMENT OF ENERGY | 2017-10-05 | — | — | US | disclosed |
| WO-2017156427-A1 | ENGINEERED SCAFFOLDS FOR VASCULARIZED TISSUE REPAIR | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-09-14 | — | — | WO | disclosed |
| US-20170174723-A1 | BI-TERMINAL PEGYLATED INTEGRIN-BINDING PEPTIDES AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-06-22 | — | — | US | disclosed |
| US-20170174722-A1 | LLP2A-BISPHOSPHONATE CONJUGATES FOR OSTEOPOROSIS TREATMENT | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-06-22 | — | — | US | disclosed |
| WO-2017099823-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF THERAPEUTIC AGENTS | MODERNATX, INC. (US) | 2017-06-15 | — | — | WO | disclosed |
| US-20170145056-A1 | Melanocortin-1 Receptor-Specific Linear Peptides | PALATIN TECHNOLOGIES INC (US) | 2017-05-25 | — | — | US | disclosed |
| EP-3131566-A1 | BI-TERMINAL PEGYLATED INTEGRIN-BINDING PEPTIDES AND METHODS OF USE THEREOF | The Regents of the University of California (US) | 2017-02-22 | — | — | EP | disclosed |
| US-9561256-B2 | LLP2A-bisphosphonate conjugates for osteoporosis treatment | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-02-07 | — | — | US | disclosed |
| US-20160368993-A1 | ALPHA-V BETA-6 INTEGRIN-BINDING ANTIBODY FRAGMENTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-12-22 | — | — | US | disclosed |
| US-9447148-B2 | Melanocortin-1 receptor-specific cyclic peptides | PALATIN TECHNOLOGIES, INC. (US) | 2016-09-20 | — | — | US | disclosed |
| US-9416162-B2 | Peptides having reduced toxicity that stimulate cholesterol efflux | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-08-16 | — | — | US | disclosed |
| WO-2016044177-A1 | PEPTIDES HAVING REDUCED TOXICITY THAT STIMULATE CHOLESTEROL EFFLUX | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-03-24 | — | — | WO | disclosed |
| US-20160074461-A1 | LLP2A-BISPHOSPHONATE CONJUGATES FOR OSTEOPOROSIS TREATMENT | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2016-03-17 | — | — | US | disclosed |
| US-20160031951-A1 | PEPTIDES HAVING REDUCED TOXICITY THAT STIMULATE CHOLESTEROL EFFLUX | UNITED STATES DEPARTMENT OF ENERGY | 2016-02-04 | — | — | US | disclosed |
| US-20160017000-A1 | RGD-CONTAINING CYCLIC PEPTIDES | UNIV CALIFORNIA (US) | 2016-01-21 | — | — | US | disclosed |
| US-9192624-B2 | Medical material and method for manufacturing same | AJINOMOTO CO., INC. (JP) | 2015-11-24 | — | — | US | disclosed |
| CN-105050614-A | Peptides having reduced toxicity that stimulate cholesterol efflux | UNIV CALIFORNIA | 2015-11-11 | — | — | CN | disclosed |
| US-9180395-B2 | Porous thin films | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-11-10 | — | — | US | disclosed |
| WO-2015160770-A1 | BI-TERMINAL PEGYLATED INTEGRIN-BINDING PEPTIDES AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-10-22 | — | — | WO | disclosed |
| US-9119884-B2 | LLP2A-bisphosphonate conjugates for osteoporosis treatment | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-09-01 | — | — | US | disclosed |
| US-9073974-B2 | RGD-containing cyclic peptides | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-07-07 | — | — | US | disclosed |
| WO-2015085179-A1 | ALPHA-V BETA-6 INTEGRIN-BINDING ANTIBODY FRAGMENTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-06-11 | — | — | WO | disclosed |
| US-20150038434-A1 | Melanocortin-1 Receptor-Specific Cyclic Peptides | PALATIN TECHNOLOGIES INC (US) | 2015-02-05 | — | — | US | disclosed |
| US-8933194-B2 | Melanocortin-1 receptor-specific linear peptides | PALATIN TECHNOLOGIES, INC. (US) | 2015-01-13 | — | — | US | disclosed |
| US-20140287994-A1 | PEPTIDES HAVING REDUCED TOXICITY THAT STIMULATE CHOLESTEROL EFFLUX | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-09-25 | — | — | US | disclosed |
| US-20140056855-A1 | LLP2A-BISPHOSPHONATE CONJUGATES FOR OSTEOPOROSIS TREATMENT | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-02-27 | — | — | US | disclosed |
| US-20130266620-A1 | MEDICAL MATERIAL AND METHOD FOR MANUFACTURING SAME | AJINOMOTO CO., INC. (JP) | 2013-10-10 | — | — | US | disclosed |
| US-8486370-B2 | Heterocyclic ligands for integrin imaging and therapy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-07-16 | — | — | US | disclosed |
| US-20130172270-A1 | RGD-CONTAINING CYCLIC PEPTIDES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-07-04 | — | — | US | disclosed |
| US-20130129972-A1 | Porous Thin Films | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-05-23 | — | — | US | disclosed |
| WO-2013032527-A1 | LLP2A-BISPHOSPHONATE CONJUGATES FOR OSTEOPOROSIS TREATMENT | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-03-07 | — | — | WO | disclosed |
| EP-2504352-A1 | MELANOCORTIN-1 RECEPTOR-SPECIFIC CYCLIC PEPTIDES | Palatin Technologies, Inc. (US) | 2012-10-03 | — | — | EP | disclosed |
| EP-2504351-A1 | MELANOCORTIN-1 RECEPTOR-SPECIFIC LINEAR PEPTIDES | Palatin Technologies, Inc. (US) | 2012-10-03 | — | — | EP | disclosed |
| US-20120225831-A1 | Melanocortin-1 Receptor-Specific Linear Peptides | PALATIN TECHNOLOGIES, INC. (US) | 2012-09-06 | — | — | US | disclosed |
| EP-2440227-A2 | MELANOCORTIN RECEPTOR-SPECIFIC PEPTIDES | Palatin Technologies, Inc. (US) | 2012-04-18 | — | — | EP | disclosed |
| US-8088890-B2 | Peptides and peptidomimetic compounds, the manufacturing thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition | FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH (AT) | 2012-01-03 | — | — | US | disclosed |
| WO-2011098095-A1 | PEPTIDES BINDING THE TPO RECEPTOR | APLAGEN GMBH (DE) | 2011-08-18 | — | — | WO | disclosed |
| EP-2334324-A2 | BBETA (15-42) AND ITS ANALOGUES COMBINED WITH CYCLOSPORINE FOR TREATMENT OF REPERFUSION INJURY | Fibrex Medical Research & Development GmbH (AT) | 2011-06-22 | — | — | EP | disclosed |
| EP-2328925-A1 | PEPTIDES AND PEPTIDOMIMETIC COMPOUNDS, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION | Fibrex Medical Research & Development GmbH (AT) | 2011-06-08 | — | — | EP | disclosed |
| EP-2328925-A1 | PEPTIDES AND PEPTIDOMIMETIC COMPOUNDS, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION | Fibrex Medical Research & Development GmbH (AT) | 2011-06-08 | — | — | EP | disclosed |
| WO-2011063367-A1 | MELANOCORTIN-1 RECEPTOR-SPECIFIC LINEAR PEPTIDES | PALATIN TECHNOLOGIES, INC. (US) | 2011-05-26 | — | — | WO | disclosed |
| WO-2011063366-A1 | MELANOCORTIN-1 RECEPTOR-SPECIFIC CYCLIC PEPTIDES | PALATIN TECHNOLOGIES, INC. (US) | 2011-05-26 | — | — | WO | disclosed |
| WO-2011060018-A2 | COMPOSITIONS AND METHODS FOR USING PEPTIDES, MODIFIED PEPTIDES, PEPTIDOMIMETICS AND FIBRIN DERIVATIVES | IKARIA DEVELOPMENT SUBSIDIARY TWO LLC (US) | 2011-05-19 | — | — | WO | disclosed |
| WO-2011060229-A1 | POROUS THIN FILMS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-05-19 | — | — | WO | disclosed |
| CN-102066416-A | Peptides, peptidomimetics and derivatives thereof, the manufacturing thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition | FIBREX MEDICAL RES & DEV GMBH | 2011-05-18 | — | — | CN | disclosed |
| US-7884074-B2 | Compounds and methods for prevention and/or treatment of inflammation using the same | Ikaria Development Subsidiary Two, LLC (US) | 2011-02-08 | — | — | US | disclosed |
| EP-2274328-A1 | PEPTIDES, PEPTIDOMIMETICS AND DERIVATIVES THEREOF, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION | Fibrex Medical Research & Development GmbH (AT) | 2011-01-19 | — | — | EP | disclosed |
| EP-2274328-A1 | PEPTIDES, PEPTIDOMIMETICS AND DERIVATIVES THEREOF, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION | Fibrex Medical Research & Development GmbH (AT) | 2011-01-19 | — | — | EP | disclosed |
| WO-2010144344-A2 | MELANOCORTIN RECEPTOR-SPECIFIC PEPTIDES | PALATIN TECHNOLOGIES, INC. (US) | 2010-12-16 | — | — | WO | disclosed |
| US-20100310455-A1 | Heterocyclic Ligands for Integrin Imaging and Therapy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-12-09 | — | — | US | disclosed |
| US-7807678-B2 | Peptidomimetics of biologically active metallopeptides | PALATIN TECHNOLOGIES, INC. (US) | 2010-10-05 | — | — | US | disclosed |
| US-7718802-B2 | Agonist or antgonist and binders and inversion of agonist; use in the treatment of metabolic, immune, infection-related and melanocortin receptor mediated disorders | PALATIN TECHNOLOGIES, INC. (US) | 2010-05-18 | — | — | US | disclosed |
| US-20100099602-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE FOR THE PREVENTION AND TREATMENT OF HYPOXIC INJURY | FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH (AT) | 2010-04-22 | — | — | US | disclosed |
| WO-2010043972-A2 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE FOR THE PREVENTION AND TREATMENT OF HYPOXIC INJURY | FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH (AT) | 2010-04-22 | — | — | WO | disclosed |
| WO-2010034041-A1 | PEPTIDES AND PEPTIDOMIMETIC COMPOUNDS, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION | FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH (AT) | 2010-04-01 | — | — | WO | disclosed |
| WO-2010034041-A1 | PEPTIDES AND PEPTIDOMIMETIC COMPOUNDS, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION | FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH (AT) | 2010-04-01 | — | — | WO | disclosed |
| US-20100081787-A1 | PEPTIDES AND PEPTIDOMIMETIC COMPOUNDS, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION | FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH (AT) | 2010-04-01 | — | — | US | disclosed |
| US-7655658-B2 | Use of in the treatment of melanocortin receptor-associated disorders such as in treatment of anorexia, as a weight gain aid, for treatment of obesity | PALATIN TECHNOLOGIES, INC. (US) | 2010-02-02 | — | — | US | disclosed |
| US-20100021379-A1 | Chemical Antibodies for Immunotherapy and Imaging | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-01-28 | — | — | US | disclosed |
| WO-2009144432-A1 | MC4-R AGONISTS FOR THE TREATMENT OF OBESITY | PALATIN TECHNOLOGIES, INC. (US) | 2009-12-03 | — | — | WO | disclosed |
| US-20090286739-A1 | PEPTIDES, PEPTIDOMIMETICS AND DERIVATIVES THEREOF, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION | FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH (AT) | 2009-11-19 | — | — | US | disclosed |
| US-20090286739-A1 | PEPTIDES, PEPTIDOMIMETICS AND DERIVATIVES THEREOF, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION | FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH (AT) | 2009-11-19 | — | — | US | disclosed |
| WO-2009137850-A1 | PEPTIDES, PEPTIDOMIMETICS AND DERIVATIVES THEREOF, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION | FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH (AT) | 2009-11-19 | — | — | WO | disclosed |
| WO-2009137850-A1 | PEPTIDES, PEPTIDOMIMETICS AND DERIVATIVES THEREOF, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION | FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH (AT) | 2009-11-19 | — | — | WO | disclosed |
| US-7576175-B2 | Amino acid terminated diphenylurea derivatives; display high binding affinity, specificity, and stability; use in treating cancer, inflammatory diseases, and autoimmune diseases | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-08-18 | — | — | US | disclosed |
| US-7550602-B1 | Small molecule compositions for sexual dysfunction | PALATIN TECHNOLOGIES, INC. (US) | 2009-06-23 | — | — | US | disclosed |
| WO-2008036449-A9 | CHEMICAL ANTIBODIES FOR IMMUNOTHERAPY AND IMAGING | UNIV CALIFORNIA (US) | 2009-02-12 | — | — | WO | disclosed |
| US-7456184-B2 | Melanocortin receptor-specific compounds | PALATIN TECHNOLOGIES INC. (US) | 2008-11-25 | — | — | US | disclosed |
| EP-1622618-A4 | MELANOCORTIN RECEPTOR-SPECIFIC COMPOUNDS | PALATIN TECHNOLOGIES INC (US) | 2008-08-27 | — | — | EP | disclosed |
| WO-2008036449-A2 | CHEMICAL ANTIBODIES FOR IMMUNOTHERAPY AND IMAGING | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-03-27 | — | — | WO | disclosed |
| WO-2008031016-A2 | HETEROCYCLIC LIGANDS FOR INTEGRIN IMAGING AND THERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-03-13 | — | — | WO | disclosed |
| US-7326707-B2 | Bicyclic melanocortin-specific compounds | PALATIN TECHNOLOGIES INCORPORATED (US) | 2008-02-05 | — | — | US | disclosed |
| EP-1669351-A2 | Method for preserving quaternary ammonium salt | Tokuyama Corporation (JP) | 2006-06-14 | — | — | EP | disclosed |
| US-7026282-B1 | Peptide antagonists of the human urokinase receptor and method for selecting them | Cancerforskningsfonden AF 1989 (Fonden Til Fremme AF Exsperimentel Cancerforskning) (DK) | 2006-04-11 | — | — | US | disclosed |
| WO-2005122379-A9 | ALPHA-4 BETA-1 INTEGRIN LIGANDS FOR IMAGING AND THERAPY | UNIV CALIFORNIA (US) | 2006-03-09 | — | — | WO | disclosed |
| EP-1622618-A1 | MELANOCORTIN RECEPTOR-SPECIFIC COMPOUNDS | Palatin Technologies, Inc. (US) | 2006-02-08 | — | — | EP | disclosed |
| US-20060019900-A1 | Alpha-4 beta-1 integrin ligands for imaging and therapy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-01-26 | — | — | US | disclosed |
| EP-1178043-B1 | METHOD FOR STORING QUATERNARY AMMONIUM SALT | TOKUYAMA CORP (JP) | 2005-12-28 | — | — | EP | disclosed |
| WO-2005122379-A2 | ALPHA-4 BETA-1 INTEGRIN LIGANDS FOR IMAGING AND THERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-12-22 | — | — | WO | disclosed |
| US-20050256056-A1 | Peptide inhibitors of HIV | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA OFFICE OF TECHNOLOGY TRANSFER UNIVERSITY OF CALIFORNIA (US) | 2005-11-17 | — | — | US | disclosed |
| WO-2005102340-A1 | PIPERAZINE MELANOCORTIN-SPECIFIC COMPOUNDS | PALATIN TECHNOLOGIES, INC. (US) | 2005-11-03 | — | — | WO | disclosed |
| US-20050176728-A1 | Agonist or antgonist and binders and inversion of agonist; use in the treatment of metabolic, immune, infection-related and melanocortin receptor mediated disorders | PALATIN TECHNOLOGIES, INC. (US) | 2005-08-11 | — | — | US | disclosed |
| US-6852856-B2 | Method for preserving quaternary ammonium salt | TOKUYAMA CORPORATION (JP) | 2005-02-08 | — | — | US | disclosed |
| WO-2004098602-A1 | MELANOCORTIN RECEPTOR-SPECIFIC COMPOUNDS | PALATIN TECHNOLOGIES, INC. (US) | 2004-11-18 | — | — | WO | disclosed |
| EP-1085000-B1 | PROCESS FOR PRODUCING CARBOXYLIC ACID DERIVATIVE AND CONDENSING AGENT COMPRISING QUATERNARY AMMONIUM SALT | TOKUYAMA CORP (JP) | 2004-10-06 | — | — | EP | disclosed |
| US-20040147740-A1 | Method for storing quaternary ammonium salt | HIRANO NAOKI (JP) | 2004-07-29 | — | — | US | disclosed |
| US-20030153785-A1 | Method for preserving quaternary ammonium salt | TOKUYAMA CORPORATION (JP) | 2003-08-14 | — | — | US | disclosed |
| US-6458948-B1 | MIXING A QUATERNARY AMMONIUM SALT HAVING A PARTICULAR TRIAZINE RING IN THE MOLECULES THEREOF, A CARBOXYLIC ACID COMPOUND AND A COMPOUND HAVING A NUCLEOPHILIC FUNCTIONAL GROUP, TO CONDENSE THE CARBOXYLIC ACID WITH THE COMPOUND HAVING THE NUCLEOPHILIC | TOKUYAMA CORPORATION (JP) | 2002-10-01 | — | — | US | disclosed |
| EP-1178043-A1 | METHOD FOR STORING QUATERNARY AMMONIUM SALT | TOKUYAMA CORPORATION (JP) | 2002-02-06 | — | — | EP | disclosed |
| EP-1085000-A1 | PROCESS FOR PRODUCING CARBOXYLIC ACID DERIVATIVE AND CONDENSING AGENT COMPRISING QUATERNARY AMMONIUM SALT | TOKUYAMA CORPORATION (JP) | 2001-03-21 | — | — | EP | disclosed |
| EP-0998476-A1 | 1,4,7,10-TETRAAZABICYCLO 8.2.2]TETRADECAN-2-ONE, A PROCESS FOR THE PREPARATION THEREOF AND THE USE THEREOF FOR THE PREPARATION OF TETRAAZAMACROCYCLES | BRACCO S.p.A. (IT) | 2000-05-10 | — | — | EP | disclosed |
| WO-2000001802-A2 | PEPTIDE ANTAGONISTS OF THE HUMAN UROKINASE RECEPTOR AND METHOD FOR SELECTING THEM | CANCERFORSKNINGSFONDEN AF 1989 (FONDEN TIL FREMME AF EKSPERIMENTEL CANCERFORSKNING) (DK) | 2000-01-13 | — | — | WO | disclosed |
| US-5965556-A | KETO-ACID AMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND METHODS FOR INHIBITING THE ACTIVITY OF SERINE PROTEASE OR THIOL PROTEASE BY ADMINISTERING THE DERIVATIVE TO A MAMMAL; ALZHEIMER'S DISEASE | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYUKAI (JP) | 1999-10-12 | — | — | US | disclosed |
| WO-1999005145-A1 | 1,4,7,10-TETRAAZABICYCLO[8.2.2]TETRADECAN-2-ONE, A PROCESS FOR THE PREPARATION THEREOF AND THE USE THEREOF FOR THE PREPARATION OF TETRAAZAMACROCYCLES | BRACCO S.P.A. (IT) | 1999-02-04 | — | — | WO | disclosed |
| US-5756763-A | ENZYME INHIBITOR | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYUKAI (JP) | 1998-05-26 | — | — | US | disclosed |
| EP-0709373-A1 | NOVEL PYRROLIDINE DERIVATIVE | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1996-05-01 | — | — | EP | disclosed |
| EP-0709373-A1 | NOVEL PYRROLIDINE DERIVATIVE | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1996-05-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (38 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10106578-B2 | Melanocortin-1 receptor-specific linear peptides | MC1R, MC5R, MC3R | TACR1 799/4885BCHE 3191/4885ACHE 3728/4885 |
| US-20100310455-A1 | Heterocyclic Ligands for Integrin Imaging and Therapy | ITGA1, ITGAL, ITGA4 | TACR1 1672/4885BCHE 4291/4885ACHE 3623/4885 |
| US-20210395302-A1 | PEPTIDES FOR ACTIVATION OF CELL SIGNALING IN OSTEOPROGENITOR CELLS | ITGB4, ITGA4, ITGB1 | TACR1 745/4885BCHE 3315/4885ACHE 3325/4885 |
| US-20050256056-A1 | Peptide inhibitors of HIV | VIP, NGLY1, PEPD | TACR1 1165/4885BCHE 1631/4885ACHE 3732/4885 |
| US-11286280-B2 | Melanocortin-1 receptor-specific peptides for cytokine storm and inflammation therapy | MC3R, MC1R, MC2R | TACR1 121/4885BCHE 3174/4885ACHE 4665/4885 |
| US-20230346960-A1 | PROTEOGLYCAN MIMETICS FOR ENHANCED WOUND HEALING, ANGIOGENESIS, AND VASCULAR REPAIR | PDGFA, PDGFRB, TEK | TACR1 2323/4885BCHE 4685/4885ACHE 4815/4885 |
| US-20100099602-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE FOR THE PREVENTION AND TREATMENT OF HYPOXIC INJURY | HIF1AN, HIF1A, EGLN3 | TACR1 435/4885BCHE 1150/4885ACHE 1258/4885 |
| US-20220313867-A1 | ENGINEERED SCAFFOLDS FOR VASCULARIZED TISSUE REPAIR | FLT4, FLT1, KDR | TACR1 250/4885BCHE 3133/4885ACHE 4739/4885 |
| US-20220363719-A1 | Reverse Amide-Linked Melanocortin Receptor-Specific Cyclic Peptides | MC1R, NPY1R, MC3R | TACR1 287/4885BCHE 2863/4885ACHE 3862/4885 |
| US-20060019900-A1 | Alpha-4 beta-1 integrin ligands for imaging and therapy | ITGA4, ITGB4, ITGA1 | TACR1 2579/4885BCHE 4476/4885ACHE 4118/4885 |
| US-20030153785-A1 | Method for preserving quaternary ammonium salt | NHERF1, ASH1L, ATP6V1B1 | TACR1 4249/4885BCHE 1646/4885ACHE 1931/4885 |
| US-20170174722-A1 | LLP2A-BISPHOSPHONATE CONJUGATES FOR OSTEOPOROSIS TREATMENT | LCP1, BST2, ITGA2B | TACR1 1389/4885BCHE 4378/4885ACHE 4402/4885 |
| US-20210093728-A1 | PROTEOGLYCAN MIMETICS FOR ENHANCED WOUND HEALING, ANGIOGENESIS, AND VASCULAR REPAIR | PDGFA, PDGFRB, TEK | TACR1 2323/4885BCHE 4685/4885ACHE 4815/4885 |
| US-20200369723-A1 | LLP2A-BISPHOSPHONATE CONJUGATES FOR OSTEOPOROSIS TREATMENT | LCP1, BST2, ITGA2B | TACR1 1389/4885BCHE 4378/4885ACHE 4402/4885 |
| US-12485182-B2 | Proteoglycan mimetics for enhanced wound healing, angiogenesis, and vascular repair | PDGFA, PDGFRB, TEK | TACR1 2323/4885BCHE 4685/4885ACHE 4815/4885 |
| US-20140056855-A1 | LLP2A-BISPHOSPHONATE CONJUGATES FOR OSTEOPOROSIS TREATMENT | LCP1, BST2, ITGA2B | TACR1 1389/4885BCHE 4378/4885ACHE 4402/4885 |
| US-20150038434-A1 | Melanocortin-1 Receptor-Specific Cyclic Peptides | MC1R, MC3R, MC5R | TACR1 104/4885BCHE 2581/4885ACHE 3984/4885 |
| US-20100081787-A1 | PEPTIDES AND PEPTIDOMIMETIC COMPOUNDS, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION | NGLY1, GHRHR, GHSR | TACR1 921/4885BCHE 3258/4885ACHE 4793/4885 |
| US-20190247539-A1 | ENGINEERED SCAFFOLDS FOR VASCULARIZED TISSUE REPAIR | FLT4, FLT1, KDR | TACR1 250/4885BCHE 3133/4885ACHE 4739/4885 |
| US-20220088146-A1 | Melanocortin Receptor-Specific Peptide Formulations and Methods for Gastrointestinal Tract-Specific Delivery | MC3R, GIPR, MC1R | TACR1 88/4885BCHE 3079/4885ACHE 4819/4885 |
| US-20230183317-A1 | METHODS OF DETECTING AND TREATING LUNG DAMAGE IN RESPIRATORY-RELATED VIRAL INFECTIONS | ACE2, ACE, MAVS | TACR1 3929/4885BCHE 3018/4885ACHE 2486/4885 |
| US-20160074461-A1 | LLP2A-BISPHOSPHONATE CONJUGATES FOR OSTEOPOROSIS TREATMENT | LCP1, BST2, ITGA2B | TACR1 1389/4885BCHE 4378/4885ACHE 4402/4885 |
| US-20260083852-A1 | PROTEOGLYCAN MIMETICS FOR ENHANCED WOUND HEALING, ANGIOGENESIS, AND VASCULAR REPAIR | PDGFA, DCLRE1A, PDGFRA | TACR1 2368/4885BCHE 3506/4885ACHE 4880/4885 |
| US-20040147740-A1 | Method for storing quaternary ammonium salt | ASNS, ATP1B2, SCN7A | TACR1 3606/4885BCHE 1645/4885ACHE 1870/4885 |
| US-20170145056-A1 | Melanocortin-1 Receptor-Specific Linear Peptides | MC1R, MC5R, MC3R | TACR1 799/4885BCHE 3191/4885ACHE 3728/4885 |
| US-20190216887-A1 | Melanocortin Receptor-Specific Peptides | MC1R, MC3R, MC4R | TACR1 128/4885BCHE 2812/4885ACHE 4312/4885 |
| US-20230040236-A1 | Diamine-Linked Melanocortin Receptor-Specific Cyclic Peptides for Ocular Indications | MC1R, MC3R, MC5R | TACR1 164/4885BCHE 2523/4885ACHE 4433/4885 |
| US-11246961-B2 | Engineered scaffolds for vascularized tissue repair | FLT4, FLT1, KDR | TACR1 250/4885BCHE 3133/4885ACHE 4739/4885 |
| US-20200339631-A1 | Melanocortin-1 Receptor-Specific Peptides for Cytokine Storm and Inflammation Therapy | MC3R, MC1R, MC2R | TACR1 121/4885BCHE 3174/4885ACHE 4665/4885 |
| US-11612663-B2 | Proteoglycan mimetics for enhanced wound healing, angiogenesis, and vascular repair | PDGFA, PDGFRB, TEK | TACR1 2323/4885BCHE 4685/4885ACHE 4815/4885 |
| US-20160017000-A1 | RGD-CONTAINING CYCLIC PEPTIDES | ITGAV, ITGB3, ITGAL | TACR1 349/4885BCHE 4392/4885ACHE 4676/4885 |
| US-10632171-B2 | Melanocortin receptor-specific peptides | MC1R, MC3R, MC4R | TACR1 128/4885BCHE 2812/4885ACHE 4312/4885 |
| US-12157778-B2 | Peptides for activation of cell signaling in osteoprogenitor cells | ITGB4, ITGA4, ITGB1 | TACR1 745/4885BCHE 3315/4885ACHE 3325/4885 |
| US-20120225831-A1 | Melanocortin-1 Receptor-Specific Linear Peptides | MC1R, MC3R, MC5R | TACR1 136/4885BCHE 3001/4885ACHE 3993/4885 |
| US-20100021379-A1 | Chemical Antibodies for Immunotherapy and Imaging | FCGR3B, FCGR2A, FCGR1A | TACR1 2706/4885BCHE 1760/4885ACHE 2840/4885 |
| US-20090286739-A1 | PEPTIDES, PEPTIDOMIMETICS AND DERIVATIVES THEREOF, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION | NPR3, RXFP3, RXFP1 | TACR1 1664/4885BCHE 2732/4885ACHE 4877/4885 |
| US-20050176728-A1 | Agonist or antgonist and binders and inversion of agonist; use in the treatment of metabolic, immune, infection-related and melanocortin receptor mediated disorders | MC3R, MC4R, MC1R | TACR1 324/4885BCHE 2727/4885ACHE 2585/4885 |
| US-20130172270-A1 | RGD-CONTAINING CYCLIC PEPTIDES | ITGAV, ITGB3, ITGAL | TACR1 349/4885BCHE 4392/4885ACHE 4676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.